Stock Market News1 month FDA Gives CRL to J&J’s BLA for Subcutaneous Rybrevant in NSCLC Zacks
The FDA issues a complete response letter to JNJ’s BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
XThe FDA issues a complete response letter to JNJ’s BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
X